Ultimovacs ASA Cash Flow Conversion Efficiency
Ultimovacs ASA cash flow conversion efficiency. Based on the latest financial reports, Ultimovacs ASA (ULTI) has a cash flow conversion efficiency ratio of -0.299x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-24.70 Million ≈ $-2.60 Million USD) by net assets (Nkr82.67 Million ≈ $8.70 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ultimovacs ASA (2016–2024)
Cash flow conversion efficiency of Ultimovacs ASA from 2016 to 2024. This chart illustrates how Ultimovacs ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ULTI stock price and chart for real-time trading data and today's change.
Ultimovacs ASA Cash Flow Conversion Ratio Explained
Ultimovacs ASA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ultimovacs ASA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ultimovacs ASA ranked by their cash flow conversion efficiency. Also see ULTI market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grupo Ezentis S.A
MC:EZE
|
-0.677x |
|
Hvidbjerg Bank
CO:HVID
|
0.002x |
|
CombinedX AB
ST:CX
|
0.135x |
|
Tailim Packaging Co Ltd
KO:011280
|
0.007x |
|
Axonics Modulation Technologies Inc
NASDAQ:AXNX
|
0.001x |
|
Hour Loop Inc
NASDAQ:HOUR
|
-0.049x |
|
Societe de Tayninh SA
PA:TAYN
|
0.000x |
|
Eloxx Pharmaceuticals, Inc.
NASDAQ:ELOX
|
-0.103x |
Annual Cash Flow Conversion Efficiency for Ultimovacs ASA (2016–2024)
The table below shows the annual cash flow conversion efficiency of Ultimovacs ASA from 2016 to 2024. Review Ultimovacs ASA (ULTI) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Nkr82.67 Million ≈ $8.70 Million |
Nkr-163.40 Million ≈ $-17.19 Million |
-1.977x | -190.92% |
| 2023-12-31 | Nkr279.39 Million ≈ $29.40 Million |
Nkr-189.83 Million ≈ $-19.98 Million |
-0.679x | -82.06% |
| 2022-12-31 | Nkr449.35 Million ≈ $47.28 Million |
Nkr-167.69 Million ≈ $-17.65 Million |
-0.373x | -75.92% |
| 2021-12-31 | Nkr593.15 Million ≈ $62.42 Million |
Nkr-125.83 Million ≈ $-13.24 Million |
-0.212x | +4.27% |
| 2020-12-31 | Nkr488.38 Million ≈ $51.39 Million |
Nkr-108.22 Million ≈ $-11.39 Million |
-0.222x | -56.42% |
| 2019-12-31 | Nkr444.63 Million ≈ $46.79 Million |
Nkr-62.99 Million ≈ $-6.63 Million |
-0.142x | +55.04% |
| 2018-12-31 | Nkr159.90 Million ≈ $16.83 Million |
Nkr-50.39 Million ≈ $-5.30 Million |
-0.315x | -92.70% |
| 2017-12-31 | Nkr166.48 Million ≈ $17.52 Million |
Nkr-27.23 Million ≈ $-2.86 Million |
-0.164x | +60.13% |
| 2016-12-31 | Nkr75.82 Million ≈ $7.98 Million |
Nkr-31.10 Million ≈ $-3.27 Million |
-0.410x | -- |
About Ultimovacs ASA
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.